15 results
Thumbnail

D1.422 - Characterization of provocation-induced changes in transcription factors in the nasal mucosa of birch pollen-allergic and non-allergic individuals

Thumbnail

D1.425 - Impact of Early Postnatal Administration of Escherichia coli O83:K24:H31 on Immune System Maturation and Gut Barrier Function

Thumbnail

D1.424 - Single-cell transcriptomic profiling of allergen-restimulated PBMCs reveals innate immune activation in equine insect bite hypersensitivity

Thumbnail

D1.430 - Extracellular vesicles isolated after cholinergic urticaria challenge carry MRGPRX2 and induce pro-inflammatory mast cell responses

Thumbnail

D1.431 - Distinct Immunophenotypic Signatures in Pediatric Allergic Disease: Clinical Utility of Methylation qPCR–Based Epigenetic TBNK Profiling

Thumbnail

D1.433 - DNA Ligase I Deficiency Masquerading as CVID-Like Phenotype: Implications for Long-Term Surveillance

Thumbnail

D1.434 - Phenotyping Common Variable Immunodeficiency by Immune Dysregulation at Diagnosis: A Descriptive Comparison of Baseline Clinical and Laboratory Findings

Thumbnail

D1.436 - Transfusion-Related Acute Lung Injury (TRALI) following plasma transfusion: A case report

Thumbnail

D1.453 - Pregnancy in Eosinophilic Granulomatosis with Polyangiitis (EGPA): a case report and literature review

Thumbnail

D1.455 - Dupilumab Efficacy in Unified Airways Disease: Pooled Analysis of Patients With Chronic Rhinosinusitis With Nasal Polyps/Allergic Fungal Rhinosinusitis With Coexisting Asthma in Ph3/4 Clinical Trials

Thumbnail

D1.457 - Clinical and immune profile of newborns born to mothers with inflammatory diseases exposed to biological drugs during pregnancy

Thumbnail

D1.460 - Diagnostic Opportunities in Type 2 Inflammations - A Machine-Learning Approach: EAACI Task Force Update

Thumbnail

D1.461 - Dupilumab as a Steroid-Sparing Treatment Option for Pemphigus Vulgaris: A Case Series from a Tertiary Centre

Thumbnail

D1.463 - Real-World Transition from Reference Omalizumab to Biosimilar Omlyclo in Patients with Chronic Urticaria: A Single-Center Descriptive Study

Thumbnail

D1.456 - Integrated Analysis of Nemolizumab Immunogenicity Indicates No Effect on the Overall Benefit-Risk Profile of Nemolizumab in Patients with Atopic Dermatitis or with Prurigo Nodularis